Sweden Living World Business Sports Entertainment Guide

Biogen

Sweden Advises Against Costly New ALS Drug Due to Limited Benefits

Sweden Advises Against Costly New ALS Drug Due to Limited Benefits

2 MIN READ

The regions are advised against using a new medication for the nervous disease ALS. The treatment is deemed too expensive and not to have any tangible impact on the patients

Upwards on Wall Street – major companies recovered

Upwards on Wall Street – major companies recovered

1 MIN READ

The trading week on Wall Street ended in major, after many large technology companies had a shaky week.

Alzheimer's drug rejected by EMA

Alzheimer's drug rejected by EMA

3 MIN READ

The Alzheimer's drug lecanemab has not been approved by the European Medicines Agency EMA. The benefits are not considered to outweigh the potential drawbacks